Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27756507 | 1.00 | BCHE (0.56) | BCHESMN1; SMN2LMNAALDH1A1CYP19A1 | |
| SCHEMBL27756497 | 0.86 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1NPC1HPGD | |
| SCHEMBL4716683 | 0.86 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1NPC1HPGD | |
| SCHEMBL28775426 | 0.81 | PTPN1 (0.59) | BCHEPOLBGALR3HSP90AA1 | |
| SCHEMBL14273826 | 0.81 | PTPN1 (0.59) | BCHEPOLBGALR3HSP90AA1 | |
| SCHEMBL4762323 | 0.81 | PTPN1 (0.59) | BCHEPOLBGALR3HSP90AA1 | |
| SCHEMBL5241817 | 0.77 | BCHE (0.59) | BCHESMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL4762125 | 0.77 | GAA (0.45) | SMN1; SMN2LMNAALDH1A1POLBPKM | |
| SCHEMBL15432250 | 0.76 | BCHE (0.66) | BCHESMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL10360638 | 0.76 | SMN1; SMN2 (0.52) | BCHESMN1; SMN2LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101404985-A | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB PUBL (SE) | 2009-04-08 | — | — | CN | disclosed |
| EP-2004159-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | Biovitrum AB (publ) (SE) | 2008-12-24 | — | — | EP | disclosed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | CYBB, NOX1, NOX5 | BCHE 1515/4885SMN1; SMN2 3440/4885LMNA 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.